Epstein David R purchased $104K of AGMB
Epstein David R purchased 15,000 shares of AgomAb Therapeutics NV (AGMB) at an average of $6.90 ($6.81–$6.98, $0.10M total) across 3 trades on 2026-11-05.
How this was made
The 30-second read
Why it matters
The modest size of the purchase limits immediate price impact, but may be noted by analysts tracking insider activity.
Market read
A small insider buy that provides a new data point but unlikely to move the stock significantly.
What to watch
Potential upcoming clinical data or regulatory events could give the buy more meaning, but are not disclosed.
Background
SEC Form 4 filing discloses insider transactions. Director purchases are monitored for signals of confidence.
Ticker impact
Director Epstein purchased 15,000 shares for $103.5K, increasing his stake to 40,000 shares.
likely modest upward pressure as market digests the insider buy
The transaction is a primary Form 4 filing, but the dollar amount is low for a mid‑cap biotech, limiting market impact.
Market effects
Minimal; insider activity does not materially affect the broader biotech sector.
None; the filing is specific to AGMB.
Low; no broader market effect.
Counterpoint
The purchase could be a routine portfolio rebalancing rather than a strong endorsement.
Key entities
- companyAgomAb Therapeutics NV
Biotech firm listed on Nasdaq under ticker AGMB.
- personEpstein David R
Director of AGMB who made the purchase.